Calquiquelignan D from Attalea butyracea Exhibits Selective Cytotoxicity Against Prostate and Skin Cancer Cells with Dual ERK2/PI3Kα Inhibitory Activity
Planta Medica · 22.09.2026
DOI: 10.1055/a-2955-9684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 22.09.2026. Verfasst von Rofida Wahman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Assiut University, Department of Pharmacognosy, Egypt, Asyut. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Skin and prostate cancers pose therapeutic challenges due to drug resistance. Attalea butyracea, a Neotropical palm with profound ethnobotanical significance, remains largely unexplored for anticancer constituents. This study aimed to isolate bioactive metabolites from A. butyracea, assess their selective cytotoxicity against A-431 and PC-3 cancer cells relative to normal cells, and explore their potential molecular targets. High-Resolution Electrospray Ionization Mass Spectrometry (HR-ESI/MS) and one- and two-dimensional nuclear magnetic resonance (1D/2D NMR) spectroscopy provided structural confirmation. Cytotoxic activity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Computational inverse docking and molecular dynamics simulations identified probable kinase targets, which were subsequently confirmed through enzyme inhibition assays. Phytochemical investigation yielded 17 compounds, including two previously undescribed glycosides, one megastigmane, and one flavonolignan. This marks the first report of flavonolignans within Attalea. Among isolated metabolites, calquiquelignan D showed notable activity, with CC50 values of 14.9 μM (A431) and 22.5 μM (PC3), comparable to those of cisplatin. Within the ATP pockets of oncogenic kinases, this compound demonstrated stable binding patterns as determined by computational analysis. Enzyme inhibition assays confirmed dual inhibition of ERK2 and PI3Kα at nanomolar concentrations. These findings suggest potential dual-pathway modulation of survival signaling. As chemotaxonomic markers with structurally distinct scaffolds, these metabolites merit further kinase-targeted drug development.
Autor:innen und Institutionen
- Faculty of Pharmacy, Assiut University, Department of Pharmacognosy, Egypt, Asyut.
- Faculty of Pharmacy, Assiut University, Pharmaceutical Organic Chemistry, Assiut Governorate, Egypt, Asyut.
- Cardiff University, School of Pharmacy & Pharmaceutical Sciences, United Kingdom of Great Britain and Northern Ireland, Cardiff.
- Technische Universität Braunschweig, Institute of Pharmaceutical Biology, Germany, Brunswick.
- Taibah University, Department of Pharmacognosy and Pharmaceutical Chemistry, Al Madinah Province, Saudi Arabia, Medina.
ORCID-Profile: Rofida Wahman, Shaymaa M M Mohamed
Zitieren
APA
Wahman, R., Mohammed, A. F., Simons, C., El-Awaad, I., & Mohamed, S. M. M. (2026). Calquiquelignan D from Attalea butyracea Exhibits Selective Cytotoxicity Against Prostate and Skin Cancer Cells with Dual ERK2/PI3Kα Inhibitory Activity. Planta Medica. https://doi.org/10.1055/a-2955-9684
Vancouver
Wahman R, Mohammed AF, Simons C, El-Awaad I, Mohamed SMM. Calquiquelignan D from Attalea butyracea Exhibits Selective Cytotoxicity Against Prostate and Skin Cancer Cells with Dual ERK2/PI3Kα Inhibitory Activity. Planta Medica. 2026. doi:10.1055/a-2955-9684
BibTeX
@article{Wahman2026,
author = {Wahman, Rofida and Mohammed, Anber F and Simons, Claire and El-Awaad, Islam and Mohamed, Shaymaa M M},
title = {Calquiquelignan D from Attalea butyracea Exhibits Selective Cytotoxicity Against Prostate and Skin Cancer Cells with Dual ERK2/PI3Kα Inhibitory Activity},
journal = {Planta Medica},
year = {2026},
doi = {10.1055/a-2955-9684}
}
EUVIMED